129 related articles for article (PubMed ID: 34297567)
1. Discovery of Cyclic Peptidomimetic Ligands Targeting the Extracellular Domain of EGFR.
Zheng M; Li C; Zhou M; Jia R; Cai G; She F; Wei L; Wang S; Yu J; Wang D; Calcul L; Sun X; Luo X; Cheng F; Li Q; Wang Y; Cai J
J Med Chem; 2021 Aug; 64(15):11219-11228. PubMed ID: 34297567
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and characterization of peptidomimetic conjugate of BODIPY targeting HER2 protein extracellular domain.
Banappagari S; McCall A; Fontenot K; Vicente MG; Gujar A; Satyanarayanajois S
Eur J Med Chem; 2013 Jul; 65():60-9. PubMed ID: 23688700
[TBL] [Abstract][Full Text] [Related]
3. Design of novel lipidated peptidomimetic conjugates for targeting EGFR heterodimerization in HER2 + cancer.
Naik H; Gauthier T; Singh S; Jois S
Bioorg Med Chem Lett; 2018 Dec; 28(22):3506-3513. PubMed ID: 30314880
[TBL] [Abstract][Full Text] [Related]
4. One-Bead-Two-Compound Thioether Bridged Macrocyclic γ-AApeptide Screening Library against EphA2.
Shi Y; Challa S; Sang P; She F; Li C; Gray GM; Nimmagadda A; Teng P; Odom T; Wang Y; van der Vaart A; Li Q; Cai J
J Med Chem; 2017 Nov; 60(22):9290-9298. PubMed ID: 29111705
[TBL] [Abstract][Full Text] [Related]
5. Peptidomimetic-based antibody surrogate for HER2.
Zheng M; Li C; Zhou M; Jia R; She F; Wei L; Cheng F; Li Q; Cai J; Wang Y
Acta Pharm Sin B; 2021 Sep; 11(9):2645-2654. PubMed ID: 34589386
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of protein-protein interaction of HER2-EGFR and HER2-HER3 by a rationally designed peptidomimetic.
Banappagari S; Corti M; Pincus S; Satyanarayanajois S
J Biomol Struct Dyn; 2012; 30(5):594-606. PubMed ID: 22731912
[TBL] [Abstract][Full Text] [Related]
7. Peptide vaccines and peptidomimetics of EGFR (HER-1) ligand binding domain inhibit cancer cell growth in vitro and in vivo.
Foy KC; Wygle RM; Miller MJ; Overholser JP; Bekaii-Saab T; Kaumaya PT
J Immunol; 2013 Jul; 191(1):217-27. PubMed ID: 23698748
[TBL] [Abstract][Full Text] [Related]
8. Inhibiting Epidermal Growth Factor Receptor Dimerization and Signaling Through Targeted Delivery of a Juxtamembrane Domain Peptide Mimic.
Gerhart J; Thévenin AF; Bloch E; King KE; Thévenin D
ACS Chem Biol; 2018 Sep; 13(9):2623-2632. PubMed ID: 30133245
[TBL] [Abstract][Full Text] [Related]
9. Design of cyclic and d-amino acids containing peptidomimetics for inhibition of protein-protein interactions of HER2-HER3.
Pallerla S; Naik H; Singh S; Gauthier T; Sable R; Jois SD
J Pept Sci; 2018 Feb; 24(2):. PubMed ID: 29436155
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth.
Yao N; Wang CR; Liu MQ; Li YJ; Chen WM; Li ZQ; Qi Q; Lu JJ; Fan CL; Chen MF; Qi M; Li XB; Hong J; Zhang DM; Ye WC
Signal Transduct Target Ther; 2020 Oct; 5(1):214. PubMed ID: 33033232
[TBL] [Abstract][Full Text] [Related]
11. Surfactant protein A down-regulates epidermal growth factor receptor by mechanisms different from those of surfactant protein D.
Hasegawa Y; Takahashi M; Ariki S; Saito A; Uehara Y; Takamiya R; Kuronuma K; Chiba H; Sakuma Y; Takahashi H; Kuroki Y
J Biol Chem; 2017 Nov; 292(45):18565-18576. PubMed ID: 28972165
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationships of peptidomimetics that inhibit PPI of HER2-HER3.
Kanthala S; Gauthier T; Satyanarayanajois S
Biopolymers; 2014 Jun; 101(6):693-702. PubMed ID: 24222531
[TBL] [Abstract][Full Text] [Related]
13. Discovery of N-(1,3,4-thiadiazol-2-yl)benzamide derivatives containing a 6,7-methoxyquinoline structure as novel EGFR/HER-2 dual-target inhibitors against cancer growth and angiogenesis.
Li XY; Wang DP; Li S; Xue WH; Qian XH; Liu KL; Li YH; Lin QQ; Dong G; Meng FH; Jian LY
Bioorg Chem; 2022 Feb; 119():105469. PubMed ID: 34915285
[TBL] [Abstract][Full Text] [Related]
14. A bispecific decoy receptor VEGFR-EGFR/Fc binding EGF-like ligands and VEGF shows potent antitumor efficacy.
Guo XF; Zhang YY; Kang J; Dou QH; Zhu XF
J Drug Target; 2022 Mar; 30(3):302-312. PubMed ID: 34319822
[TBL] [Abstract][Full Text] [Related]
15. Discovery of highly potent and selective EGFR
Yang T; Zhang W; Cao S; Sun S; Cai X; Xu L; Li P; Zheng Z; Li S
Eur J Med Chem; 2022 Jan; 228():113984. PubMed ID: 34794818
[TBL] [Abstract][Full Text] [Related]
16. Fulvestrant regulates epidermal growth factor (EGF) family ligands to activate EGF receptor (EGFR) signaling in breast cancer cells.
Zhang X; Diaz MR; Yee D
Breast Cancer Res Treat; 2013 Jun; 139(2):351-60. PubMed ID: 23686416
[TBL] [Abstract][Full Text] [Related]
17. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
18. Retinoids suppress epidermal growth factor-associated cell proliferation by inhibiting epidermal growth factor receptor-dependent ERK1/2 activation.
Sah JF; Eckert RL; Chandraratna RA; Rorke EA
J Biol Chem; 2002 Mar; 277(12):9728-35. PubMed ID: 11788593
[TBL] [Abstract][Full Text] [Related]
19. Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy.
van der Veeken J; Oliveira S; Schiffelers RM; Storm G; van Bergen En Henegouwen PM; Roovers RC
Curr Cancer Drug Targets; 2009 Sep; 9(6):748-60. PubMed ID: 19754359
[TBL] [Abstract][Full Text] [Related]
20. Effective degradation of EGFR
Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
